Ann: Remplir Gains Australian Reimbursement, page-45

This market (almost) cracks me up. This stock now trading near levels BEFORE the Bio Horizons deal, that smoked even the most optimistic of OCC's investors expectations of a Striate deal.

Its just confirmed its on the Australian prothesis list at a very handsome $1,354. A medical market that is invariably cheaper than the US on practically any aspect you'd like to compare - I can get an MRI for $250 in central Sydney, I could not get one for less than $750 in the US.

Addressable market of some 12,000 nerve repairs in Australia. Lets be conservative and say 1,000 for 2023 CY. Just $1,354,000 gross revenue.
Not that impressive. Except, given the well stated confidentiality of the agreement, there were many investors with concerns over what Orthocell would charge Bio Horizons wholesale for Striate. This Remplir news gives very important insight into the wholesale cost of Striate.

Remplir and Striate are essentially the same product. We know OCC just raised its production to 100,000 per annum on the back of the Bio Horizons deal. We know BH sells way more membranes than that annually with a little research (Striate will not be the only membrane in its suite of dental graft membranes/biologics). Even using very conservative prices and volumes for Striate, you have to expect OCC to go cash flow positive in 2023....and then some. An $80M market cap for this stock given its probable and potential forward revenues is ridiculous.